| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Kansuinine B targets the IL-6/Stat3 signaling pathway. By inhibiting IL-6-induced Stat3 activation, the compound modulates inflammatory and immune responses. Stat3 is a transcription factor that plays a critical role in cell proliferation, survival, and inflammation. The compound's inhibition of Stat3 activation underlies its anti-inflammatory and immunoregulatory activities.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Kansuinine B inhibits IL-6-induced Stat3 activation. The compound's inhibition of Stat3 can be assessed using cell-free assays with purified Stat3 protein and its upstream kinases. The compound shows cytotoxic activity in cell-free systems. It also exhibits antiviral activity.
|
| ln Vivo |
In cell-based assays, Kansuinine B inhibits IL-6-induced Stat3 activation, leading to reduced inflammatory responses. The compound shows cytotoxic activity against cancer cells and possesses immunoregulatory activity. It has been studied for antiviral host response pathways and could be used in the study for COVID-19.
|
| Enzyme Assay |
The cell-free assay for Stat3 activation involves measuring the phosphorylation of Stat3 protein. The compound is incubated with purified Stat3 and its upstream kinases in the presence of IL-6, and the phosphorylation of Stat3 is measured using Western blotting or ELISA. The compound's inhibition of Stat3 activation is determined from dose-response curves. Cytotoxicity can be assessed using standard cell-free assays.
|
| Cell Assay |
Cell-based assays for Kansuinine B involve culturing relevant cell lines and treating them with the compound at concentrations ranging from 0.1 to 100 μM. IL-6-induced Stat3 activation is assessed by measuring Stat3 phosphorylation by Western blotting. Cell viability is assessed using MTT or CCK-8 assays. Antiviral activity is assessed by measuring viral replication in infected cells. The compound's immunoregulatory effects are evaluated by measuring cytokine production.
|
| Animal Protocol |
There is no established animal experimental protocol for Kansuinine B specifically. As a natural compound with anti-inflammatory, immunoregulatory, and antiviral activities, it could potentially be evaluated in animal models of inflammation, viral infection, or cancer. Typical studies involve administration of the compound to mice via oral or intraperitoneal routes. Inflammatory markers, viral load, and tumor growth would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Kansuinine B have not been extensively reported. As a complex natural product with a molecular weight of 722.73 g/mol, the compound would be expected to have limited oral bioavailability and may require parenteral administration. The compound is typically stored at low temperatures for research use. Further pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Kansuinine B is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a compound with cytotoxic and immunomodulatory activities, it may have effects on normal cells as well as cancer cells. Standard toxicity studies would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Kansuinine B is a benzoic acid ester. It has been reported that Kansuinine B exists in the genus Euphorbia kansui, and relevant data are available for reference.
Kansuinine B is a research-grade natural product from Euphorbia kansui L. It is not an approved pharmaceutical and has no clinical trial history. The compound inhibits IL-6-induced Stat3 activation, possesses antiviral activity, and could be used in the study for COVID-19. It also shows cytotoxic and analgesic activities. This product is intended for research use only. |
| Molecular Formula |
C38H42O14
|
|---|---|
| Molecular Weight |
722.73
|
| Exact Mass |
722.257
|
| CAS # |
57685-46-8
|
| PubChem CID |
442050
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.911
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
52
|
| Complexity |
1460
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@H]1[C@H]2[C@@H](O2)C(C(=O)[C@@H]([C@H](C(=C)[C@@H]([C@H]3[C@H]([C@]([C@@H]([C@@]3(C1=O)OC(=O)C)O)(C)O)OC(=O)C)OC(=O)C4=CC=CC=C4)OC(=O)C5=CC=CC=C5)O)(C)C
|
| InChi Key |
JFOILMZFESGPDU-GXRLDEOZSA-N
|
| InChi Code |
InChI=1S/C38H42O14/c1-18-26(50-33(44)22-14-10-8-11-15-22)24-31(48-20(3)39)37(7,47)35(46)38(24,52-21(4)40)29(42)19(2)28-32(49-28)36(5,6)30(43)25(41)27(18)51-34(45)23-16-12-9-13-17-23/h8-17,19,24-28,31-32,35,41,46-47H,1H2,2-7H3/t19-,24-,25+,26-,27-,28-,31+,32+,35-,37-,38+/m0/s1
|
| Chemical Name |
[(1S,3S,4S,6S,9R,10S,12R,13S,14R,15R,16S)-1,14-diacetyloxy-10-benzoyloxy-9,15,16-trihydroxy-3,7,7,15-tetramethyl-11-methylidene-2,8-dioxo-5-oxatricyclo[11.3.0.04,6]hexadecan-12-yl] benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3836 mL | 6.9182 mL | 13.8364 mL | |
| 5 mM | 0.2767 mL | 1.3836 mL | 2.7673 mL | |
| 10 mM | 0.1384 mL | 0.6918 mL | 1.3836 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
